載入...
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community
Biosimilars are highly similar versions of approved branded biologics. Unlike generics, they are not exact replicas of reference products. Minor differences between biosimilars and reference products in some aspects are expected; likewise, biosimilar products will differ from each other. The objecti...
Na minha lista:
| 發表在: | BioDrugs |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443883/ https://ncbi.nlm.nih.gov/pubmed/28439817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-017-0218-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|